within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BX17_Carfloglitazar;

model Carfloglitazar
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 1.111111111111111e-06,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.05,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Carfloglitazar</td></tr><tr><td>ATC code:</td><td>A10BX17</td></tr><td>route:</td><td>orally</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>50</td><td>L</td></tr>
    <tr><td>clearance:</td><td>4</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Carfloglitazar is a dual PPAR alpha and gamma agonist developed for the treatment of type 2 diabetes mellitus. It works by improving insulin sensitivity and modulating lipid metabolism. As of 2024, carfloglitazar is not an approved or marketed drug and was primarily investigated in early-phase clinical trials.</p><h4>Pharmacokinetics</h4><p>No published clinical pharmacokinetic studies are available for carfloglitazar in humans. The following parameters are estimated based on typical values for drugs in this class (PPAR agonists) and preclinical information.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A10BX17 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Carfloglitazar;
